Biopharma heavyweight Bristol‑Myers Squibb will equip more than 30,000 of its employees with Anthropic’s flagship large‑language model Claude. The rollout, slated for public disclosure on Wednesday, embeds the AI tool across research labs, clinical‑development teams and corporate units. By standardising Claude’s agents, BMS aims to streamline data‑intensive workflows, cut cycle times and ensure compliance with data‑privacy standards.

Anthropic has made life sciences a cornerstone of its enterprise strategy. Eric Kauderer‑Abrams, the firm’s head of life sciences, described the sector as a “significant investment area,” reflecting the industry’s appetite for AI‑driven drug discovery and trial optimization. Both firms plan joint pilots to benchmark Claude against internal models. The partnership with BMS marks the company’s deepest penetration of a major pharmaceutical client to date.

Deploying Claude at scale gives BMS a tool to accelerate candidate screening and automate routine reporting, potentially shaving months off development timelines. Investors will watch whether the AI infusion translates into measurable cost savings or faster approvals, a benchmark that could spur rival firms to adopt similar platforms. Early tests show 20% cut. The move signals an accelerating convergence of pharma and generative AI.